Unknown

Dataset Information

0

Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.


ABSTRACT: BACKGROUND/AIM:The Philadelphia chromosome is considered the hallmark of chronic myeloid leukemia (CML). However, although most patients with CML are diagnosed with the e13a2 or e14a2 breakpoint cluster region (BCR)-Abelson 1 (ABL1) fusion transcripts, about 5% of them carry rare BCR-ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3 and e6a2. In particular, the e6a2 fusion transcript has been associated with clinically aggressive disease frequently presenting in accelerated or blast crisis phases; there is limited evidence on the efficacy of front-line second-generation tyrosine kinase inhibitors for this genotype. CASE REPORT:We describe a case of atypical BCR-ABL1 e6a2 fusion transcript in a 46-year-old woman with CML. RESULTS:The use of primers recognizing more distant exons from the common BCR-ABL1 breakpoint region correctly identified the atypical BCR-ABL1 e16a2 fusion transcript. Treatment with second-generation tyrosine kinase inhibitor nilotinib was effective in this patient expressing the atypical e6a2 BCR-ABL1 fusion transcript.

SUBMITTER: Manzella L 

PROVIDER: S-EPMC7279803 | biostudies-literature | 2020 May-Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Optimal Response in a Patient With CML Expressing <i>BCR-ABL1</i> E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Manzella Livia L   Tirrò Elena E   Vitale Silvia Rita SR   Puma Adriana A   Consoli Maria Letizia ML   Tambè Loredana L   Pennisi Maria Stella MS   DI Gregorio Sandra S   Romano Chiara C   Tomarchio Cristina C   DI Raimondo Francesco F   Stagno Fabio F  

In vivo (Athens, Greece) 20200501 3


<h4>Background/aim</h4>The Philadelphia chromosome is considered the hallmark of chronic myeloid leukemia (CML). However, although most patients with CML are diagnosed with the e13a2 or e14a2 breakpoint cluster region (BCR)-Abelson 1 (ABL1) fusion transcripts, about 5% of them carry rare BCR-ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3 and e6a2. In particular, the e6a2 fusion transcript has been associated with clinically aggressive disease frequently presenting in accelerate  ...[more]

Similar Datasets

| S-EPMC5662812 | biostudies-other
| S-EPMC3548169 | biostudies-literature
| S-EPMC7439560 | biostudies-literature
| S-EPMC7922348 | biostudies-literature
| S-EPMC5354859 | biostudies-other
| S-EPMC6700306 | biostudies-literature
| S-EPMC2652262 | biostudies-literature
| S-EPMC2291110 | biostudies-literature
| S-EPMC3859659 | biostudies-literature